SCHEMBL7240664

SCHEMBL7240664

COC(=O)CC1=C(C(=O)OC)C(c2c(Cl)cccc2Cl)C(C(=O)OC)=C(CCc2ccccc2OCCNC(c2ccccc2)(c2ccccc2)c2ccccc2)N1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 1/20 0.33
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
PKM P14618 1/20 0.32
ADRA1A P35348 4/20 0.31
HTR1A P08908 3/20 0.31
TBXA2R P21731 3/20 0.31
SLC6A3 Q01959 3/20 0.31
ADRA2A P08913 2/20 0.31
CHRM1 P11229 2/20 0.31
DRD1 P21728 2/20 0.31
SLC6A2 P23975 2/20 0.31
OPRM1 P35372 2/20 0.31
DRD3 P35462 2/20 0.31
KCNH2 Q12809 2/20 0.31
ADRA1D P25100 2/20 0.31
ADRA1B P35368 2/20 0.31
ABCB11 O95342 2/20 0.31
ABCB1 P08183 2/20 0.31
ADORA3 P0DMS8 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6940682 0.92 PPARD (0.35) PPARDMEN1KMT2APKMADRA1A
SCHEMBL6152772 0.89 TBXA2R (0.36) MEN1KMT2AADRA1AHTR1ATBXA2R
SCHEMBL7247859 0.84 HTR1A (0.35) ADRA1AHTR1ATBXA2RSLC6A3ADRA2A
SCHEMBL6152961 0.83 HTR1A (0.30) ADRA1AHTR1ATBXA2RSLC6A3ADRA2A
SCHEMBL6942911 0.80 ABCB11 (0.33) MEN1KMT2AADRA1AHTR1ATBXA2R
SCHEMBL6940628 0.80 CYP2C9 (0.36) MEN1KMT2AADRA1AHTR1ATBXA2R
SCHEMBL6945502 0.80 HSD17B10 (0.36) MEN1KMT2AADRA1AHTR1ATBXA2R
SCHEMBL6154618 0.80 KDM4E (0.36) MEN1KMT2AADRA1AHTR1ATBXA2R
SCHEMBL7843083 0.79 ALDH1A1 (0.41) MEN1KMT2AGAAALDH1A1KDM4E
SCHEMBL6153193 0.79 LMNA (0.36) MEN1KMT2AADRA1AHTR1ATBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653313-B2 For treatment and prevention of inflammation, asthma, allergic rhinitis, pain and other disorders WARNER-LAMBERT COMPANY LLC 2003-11-25 US disclosed
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists KAWAMURA MITSUHIRO (US) 2002-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161006-A1 1,4-dihydropyridine compounds as bradykinin antagonists BDKRB1, BDKRB2, HRH4 PPARD 4092/4885MEN1 2435/4885KMT2A 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.